Registry for young women with certain early breast cancer treatments
Part of Cancer, Skin clinical trials.
This registry collects information from pre- or perimenopausal women with early breast cancer who are treated with standard care, plus tumor testing like MammaPrint®. It may help doctors better understand which treatments work best for different risk groups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with breast cancer and you are pre- or perimenopausal (often under 60, and not having a period for less than 12 months after surgery/cessation).
- Your breast cancer was diagnosed recently (within about 3 months of the initial biopsy).
- Your tumor is hormone-receptor positive (estrogen and/or progesterone) and HER2 negative, and there are no signs of spread on exam/scans.
- Your doctor categorizes you as intermediate or high risk for recurrence, AND your tumor test shows low risk by MammaPrint® and a luminal type by BluePrint®.
- You have a tumor sample available for testing (for example, an untreated core biopsy or a surgery specimen).
- You can sign informed consent and you are not currently in a drug/immunotherapy/antibody treatment study for any cancer. (Also, you must not have had other gene tests on the tumor besides MammaPrint®).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how genetic tests like Oncotype DX or Mammaprint are used to guide treatment decisions for people with early-stage, hormone receptor-positive (HR+) and HER2-negative breast cancer. It aims to help doctors choose between hormone therapy alone or chemotherapy plus hormone therapy.
This trial studies early, hormone receptor–positive, HER2-negative breast cancer and looks at a group with “high clinical risk” but “low genetic (tumor) risk.” It may help researchers understand which patients may benefit most from treatment decisions guided by genetic tumor testing.
This trial looks back at premenopausal women with early-stage, hormone-positive, HER2-negative breast cancer who had surgery and an Oncotype DX test, to see how different treatments affected their outcomes. If you fit this group, your past medical records could help researchers learn more about the best treatments.
This study collects health and treatment information from people with breast cancer that cannot be fully removed by surgery or that has spread to other parts of the body. It may help researchers better understand which treatments are used and how people do over time.
This study observes how doctors treat early breast cancer and what outcomes patients have. It's for people with hormone receptor-positive, HER2-negative breast cancer that hasn't spread to many lymph nodes.
This trial studies whether younger, premenopausal women with early-stage, hormone-sensitive breast cancer can safely use hormone therapy alone after surgery, based on their tumor's gene activity score (Oncotype DX). It aims to find the best treatment approach based on your cancer's biology.
Hear when a new Female Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.